Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo

Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., et al. (1991). Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine, 781-788.

Type

Journal article

Intellectual base

Primary research

Year

1991

DOI

10.1056/nejm199103213241201

Link

https://doi.org/10.1056/NEJM199103213241201

Cited from

statistics_experimental_design

Cited by

1 citation across 1 artifact.

Primes

• Proxy–Target Fidelity
  • And the substitution risk is realized in documented cases where a drug improved the surrogate (suppressed arrhythmias, raised HDL, lowered glucose) while increasing mortality — the proxy moved the intended way and the target moved the opposite way, the exact catastrophe of treating a stand-in as the thing.

Verification

This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.

Registry ID ref:b5fd0547653d · see in the full table